NOTCH3 and acute lymphoblastic leukemia: Notably, interesting results obtained from patient-derived T-ALL cells (PDTALLs)17 (Supplementary Fig. S8a) suggested the potential clinical relevance of the Juglone, as we observed that Juglone treatment is able to reduce Notch3 protein expression and to induce T-ALL cell death in a dose-dependent manner (Supplementary Fig. S8b).